CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele

Pharmacogenetics and Genomics

Volumn 15, Issue 9, 2005, Pages 625-631

  Sim, Sarah C ^a   Edwards, Robert J ^b   Boobis, Alan R ^b   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cytochrome P450; Dehydroepiandrosterone; Genetic polymorphism; Peptide antibody

Indexed keywords

CYTOCHROME P450 3A7; ENZYME ANTIBODY; PRASTERONE; RETINOIC ACID;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; MICROSOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TISSUE LEVEL; WESTERN BLOTTING;

EID: 23444432323     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000171516.84139.89     Document Type: Article

References (28)

1. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625-634.
2. Schuetz JD, Beach DL, Guzelian PS. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 1994; 4:11-20.
3. Greuet J, Pichard L, Bonfils C, Domergue J, Maurel P. The fetal specific gene CYP3A7 is inducible by rifampicin in adult human hepatocytes in primary culture. Biochem Biophys Res Commun 1996; 225:689-694.
4. Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H, et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 2002; 277:24280-24288.
5. Koch I, Weil R, Wolbold R, Brockmoller J, Mustert E, Burk O, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30:1108-1114.
6. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391.
7. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, Zaya MJ. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003; 307:573-582.
8. Boobis AR, Brodie MJ, Kahn GC, Fletcher DR, Saunders JH, Davies DS. Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol 1980; 9:11-19.
9. Edwards RJ, Adams DA, Watts PS, Davies DS, Boobis AR. Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 1998; 56:377-387.
10. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
11. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003; 31:755-761.
12. Schulz-Utermoehl T, Edwards PJ, Boobis AR. Affinity and potency of proinhibitory antipeptide antibodies against CYP2D6 is enhanced using cyclic peptides as immunogens. Drug Metab Dispos 2000; 28: 544-551.
13. Burk O, Wojnowski L. Cytochrome P450 3A and their regulation. Naunyn Schmiedeberg's Arch Pharmacol 2004; 369:105-124.
14. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-1294.
15. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 2004; 26:192-199.
16. Pascussi JM, Jounaidi Y, Drocourt L, Domergue J, Balabaud C, Maurel P, Vilarem MJ. Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem Biophys Res Commun 1999; 260:377-381.
17. Tateishi T, Nakura H, Asoh M, Watanabe M, Tanaka M, Kumai T, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci 1997; 61:2567-2574.
18. Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 1999; 57:935-939.
19. Hakkola J, Raunio H, Purkunen R, Saarikoski S, Vahakangas K, Pelkonen O, et al. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol Neonate 2001; 80:193-201.
20. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30:883-891.
21. Miller KK, Cai J, Ripp SL, Pierce WM Jr, Rushmore TH, Prough RA. Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450. Drug Metab Dispos 2004; 32:305-313.
22. Marill J, Cresteil T, Lanotte M, Chabot GG. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 2000; 58:1341-1348.
23. Marill J, Capron CC, Idres N, Chabot GG. Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. Biochem Pharmacol 2002; 63:933-943.
24. Niles RM. Signaling pathways in retinoid chemoprevention and treatment of cancer. Mutat Res 2004; 555:81-96.
25. Jimenez-Lara AM, Clarke N, Altucci L, Gronemeyer H. Retinoic-acid-induced apoptosis in leukemia cells. Trends Mol Med 2004; 10:508-515.
26. Cooper AJ. Treatment of acne with isotretinoin: recommendations based on Australian experience. Austral J Dermatol 2003; 44:97-105.
27. Binello E, Gordon CM. Clinical uses and misuses of dehydroepiandrosterone. Curr Opin Pharmacol 2003; 3:635-641.
28. Rodriguez-Antona C, Jande M, Rane A, Ingelman-Sundberg M. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharm Ther 2005; 77: 259-270.